Skip to main content

Table 1 Results from cell and cell tumour experiments

From: Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo

Cell line IC50 (mean ± SEM) Tumour growth inhibition in vivo by R115777 Ras statusa ERa EGFRa HER2a
   50 mg/kg 100 mg/kg     
SK-BR3 39.0 ± 25.8 nmol/l - - Wild-type - + ++
MCF-7 46.0 ± 5.0 nmol/l - - Wild-type, over-expression of n-ras ++ + (+)
MCF-7/HER2-18 60.3 ± 117 nmol/l 80.8% 95.9% Wild-type, over-expression of n-ras ++ + +++
BT474 195 ± 119 nmol/l - - Wild-type + - ++
SKOV3 2.7 ± 0.4 μmol/l 60.1% 20.4% Wild-type - ++ +++
MDA-MB231 5.9 ± 0.8 μmol/l -68.8% -91.2% Mutated k-ras - +++ +
  1. The table shows the concentration of R115777 required to reduce cell numbers by 50% (50% inhibitory concentration [IC50]), inhibition by R115777 at two different doses in tumours grown in athymic mice, and receptor and ras status for the different cancer cell lines. aData collected from the literature [4,12,46]. EGFR, epidermal growth factor receptor; ER, oestrogen receptor; SEM, standard error of the mean.
\